Glenmark Pharmaceuticals Recalls 1,200 Bottles Of Hypertension Drug In US

New Delhi : Glenmark Pharmaceuticals is recalling 1,200 bottles of a generic drug, used to treat high blood pressure, in the American market due to a manufacturing issue, according to the US Food and Drug Administration (USFDA).

The New Jersey-based arm of the drug firm is recalling 1,200 bottles of Trandolapril and Verapamil Hydrochloride extended-release tablets, Batch # 19224744 as per the latest Enforcement Report of the US health regulator.

The affected lot has been manufactured at the Goa plant of the Mumbai-based drug firm and then supplied to Glenmark Pharmaceuticals Inc, USA, the USFDA said.

The firm is recalling the affected bottles due to it being “Subpotent”, it noted.

Subpotent means ‘Out of Specification for Assay Test at the 3-month time point.’

Glenmark Pharmaceuticals Inc initiated the nationwide (US) Class III recall on August 14 this year, it added.

As per the USFDA, a Class III recall is initiated in a “situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences”.

Related Posts

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

New Delhi: In a major crackdown on the sale of expired and substandard products, the Central Range team of Delhi Police Crime Branch has arrested one person and seized nearly…

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

Washington:  On March 18, 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled General Considerations for the Use of New Approach Methodologies in Drug Development. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

Delhi Crime Branch Seizes Huge Stock Of Expired Baby Food, Cosmetics; One Arrested

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

FDA Releases Draft Guidance To Validate Non-Animal Testing Methods (NAMs) In Drug Development

IPC releases draft NFI-2026 to promote rational use of medicines

IPC releases draft NFI-2026 to promote rational use of medicines

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

Moonshot, SS Innovations displayed Battle Readiness for Monumental Goals in Robotic Surgery

US market to dent India pharma earnings even as domestic growth remains firm

US market to dent India pharma earnings even as domestic growth remains firm

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg

Biocon Pharma receives USFDA approval for Dapagliflozin Tablets, 5 mg and 10 mg